Evicenter
P&T meetings

Tovecimig

Second-line advanced biliary tract cancer

Also known as CTX-009, ABL001
89 sources

Section 6 of 6

References

89 sources

  1. Abou-Alfa et al. (2020) (opens in a new tab)
  2. ASCO Daily News (2026) (opens in a new tab)
  3. Azad et al. (2024) (opens in a new tab)
  4. Banales et al. (2020) (opens in a new tab)
  5. Benson et al. (2025) (opens in a new tab)
  6. Boilève et al. (2026) (opens in a new tab)
  7. Brindley et al. (2021) (opens in a new tab)
  8. Burris et al. (2024) (opens in a new tab)
  9. CancerNetwork (2026) (opens in a new tab)
  10. Chamberlain et al. (2021) (opens in a new tab)
  11. Chen et al. (2024a) (opens in a new tab)
  12. Chen et al. (2024b) (opens in a new tab)
  13. Chueh et al. (2023) (opens in a new tab)
  14. ClinicalTrials.gov NCT03292783 (opens in a new tab)
  15. ClinicalTrials.gov NCT04492033 (opens in a new tab)
  16. ClinicalTrials.gov NCT05506943 (opens in a new tab)
  17. ClinicalTrials.gov NCT05513742 (opens in a new tab)
  18. ClinicalTrials.gov NCT05513742 results (opens in a new tab)
  19. ClinicalTrials.gov NCT06548412 (opens in a new tab)
  20. ClinicalTrials.gov NCT07392957 (opens in a new tab)
  21. ClinicalTrials.gov NCT07662031 (opens in a new tab)
  22. Compass Therapeutics 2025 results announcement (2026) (opens in a new tab)
  23. Compass Therapeutics COMPANION-002 data presentation (2026) (opens in a new tab)
  24. Compass Therapeutics COMPANION-002 primary endpoint announcement (2025) (opens in a new tab)
  25. Compass Therapeutics COMPANION-002 survival data announcement (2026) (opens in a new tab)
  26. Compass Therapeutics corporate presentation (2026) (opens in a new tab)
  27. Compass Therapeutics corporate update (2025) (opens in a new tab)
  28. Compass Therapeutics corporate update (2026) (opens in a new tab)
  29. Compass Therapeutics Fast Track designation announcement (2024) (opens in a new tab)
  30. Compass Therapeutics first quarter results announcement (2026) (opens in a new tab)
  31. Compass Therapeutics Form 10-K (2026) (opens in a new tab)
  32. Compass Therapeutics Form 10-Q (2026) (opens in a new tab)
  33. Compass Therapeutics second quarter results announcement (2026) (opens in a new tab)
  34. DelveInsight (2026) (opens in a new tab)
  35. Ferraz Gonçalves et al. (2021) (opens in a new tab)
  36. Giuliani et al. (2026) (opens in a new tab)
  37. Gordon et al. (2021) (opens in a new tab)
  38. Goyal et al. (2023) (opens in a new tab)
  39. Harding et al. (2023) (opens in a new tab)
  40. Javle et al. (2022) (opens in a new tab)
  41. Javle et al. (2026) (opens in a new tab)
  42. Jimeno et al. (2019) (opens in a new tab)
  43. Kaupp-Roberts et al. (2016) (opens in a new tab)
  44. Kelley et al. (2023) (opens in a new tab)
  45. Kim et al. (2020) (opens in a new tab)
  46. Korea Biomedical Review (2026) (opens in a new tab)
  47. Lamarca et al. (2021) (opens in a new tab)
  48. Lamarca et al. (2026) (opens in a new tab)
  49. Lang et al. (2024) (opens in a new tab)
  50. Lee et al. (2021) (opens in a new tab)
  51. Li et al. (2025) (opens in a new tab)
  52. Mancarella et al. (2020) (opens in a new tab)
  53. Meric-Bernstam et al. (2024) (opens in a new tab)
  54. Na et al. (2024) (opens in a new tab)
  55. Nakamura et al. (2023) (opens in a new tab)
  56. Nakaoka et al. (2026) (opens in a new tab)
  57. NICE TA1153 committee discussion (2026) (opens in a new tab)
  58. NICE TA1153 recommendation (2026) (opens in a new tab)
  59. Oh et al. (2022) (opens in a new tab)
  60. Oh et al. (2023) (opens in a new tab)
  61. Oh et al. (2025) (opens in a new tab)
  62. Pant et al. (2026) (opens in a new tab)
  63. Parasuraman et al. (2023) (opens in a new tab)
  64. Rocha-Gomes et al. (2026) (opens in a new tab)
  65. Roskoski (2024) (opens in a new tab)
  66. Rousian et al. (2026) (opens in a new tab)
  67. SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026) (opens in a new tab)
  68. Shroff et al. (2025) (opens in a new tab)
  69. Siegel et al. (2026) (opens in a new tab)
  70. Subbiah et al. (2020) (opens in a new tab)
  71. Sung et al. (2026) (opens in a new tab)
  72. Van Dyke et al. (2019) (opens in a new tab)
  73. Verma et al. (2025) (opens in a new tab)
  74. Vogel and Ducreux (2025) (opens in a new tab)
  75. Vogel et al. (2023) (opens in a new tab)
  76. Vogel et al. (2024a) (opens in a new tab)
  77. Vogel et al. (2024b) (opens in a new tab)
  78. Wang et al. (2024) (opens in a new tab)
  79. Wang et al. (2026) (opens in a new tab)
  80. Xiao et al. (2025) (opens in a new tab)
  81. Ye et al. (2023) (opens in a new tab)
  82. Yeom et al. (2020) (opens in a new tab)
  83. Yoo et al. (2021) (opens in a new tab)
  84. Yoo et al. (2025a) (opens in a new tab)
  85. Yoo et al. (2025b) (opens in a new tab)
  86. Yoon and Yoo (2026) (opens in a new tab)
  87. Zhang et al. (2026) (opens in a new tab)
  88. Zhou et al. (2025) (opens in a new tab)
  89. Zhu et al. (2021) (opens in a new tab)